clinical trial · NCT06592768
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Allergic AsthmaBriquilimabPlacebo Comparator
brief summary
Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model. A single dose proof of concept approach at a dose level shown to be biologically active should inform the impact of briquilimab on allergic asthma as compared to placebo while minimizing exposure to participants, in a new indication.
started
Nov 26, 2024
primary completion
Aug 11, 2025
completion
Aug 11, 2025
last updated
Sep 16, 2025
official title
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol